Please note most of these publications were published by our predecessor company CellPoint, LLC.

Cell>Point completes clinical pilot study on 99mTc-EC-Annexin V — 4|1|04

HOUSTON,Texas-April1,2004 -Cell>Point L.L.C. completes clinical pilot study on 99mTc-EC-Annexin V at The University of Texas M.D. Anderson Cancer Center. The study evaluated the use of 99mTc-EC-Annexin V to assess tumor apoptosis (programmed cell death) in patients with primary breast cancer and to detect and image treatment related apoptosis in patients with primary breast cancer. The images produced in the study exceeded the company’s expectations. By using 99mTc-EC-Annexin V, the oncologist will be able to detect cell death much more quickly than current practice.